IMMUNOLOGY Correction for “Anti–IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function,” by Li-Fen Lee, Kathryn Logronio, Guang Huan Tu, Wenwu Zhai, Irene Ni, Li Mei, Jeanette Dilley, Jessica Yu, Arvind Rajpal, Colleen Brown, Charles Appah, Sherman Michael Chin, Bora Han, Timothy Affolter, and John C. Lin, which appeared in issue 31, July 31, 2012, of Proc Natl Acad Sci USA (109:12674–12679; first published June 25, 2012; 10.1073/pnas.1203795109).
The authors note that their conflict of interest statement was omitted during publication. The authors declare that all the authors are full-time employees of Pfizer Inc. Pfizer Inc. filed a patent application, with L.F.-L., J.C.L., and W.Z. as co-inventors: US Application Serial No. 13/033,491, entitled “Antagonist Anti-IL-7 Receptor Antibodies and Methods.”